Managed Healthcare Executive June 4, 2020
In 2019, there were 10 new biosimilar approved by the FDA, which followed seven in 2018, five in 2017, three in 2016, and the inaugural approved biosimilar in 2015.
Those approved last year include help for rheumatoid arthritis, plaque psoriasis, breast cancer, metastatic stomach cancer, metastatic colorectal cancer, nonsquamous nonsmall cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, B-cell non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.
The biosimilar approvals “will further help to create competition, increase patient access, and potentially reduce the cost of important biological drug therapies,” the FDA said.
While the numbers have gone up each year, many in the healthcare industry believe it’s still slow.
Patti Seymour, MBA, CSCP, managing director...